Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 227.79M P/E - EPS this Y - Ern Qtrly Grth -
Income -205.6M Forward P/E -1.86 EPS next Y - 50D Avg Chg -9.00%
Sales 3.49M PEG - EPS past 5Y - 200D Avg Chg -29.00%
Dividend N/A Price/Book 0.08 EPS next 5Y 26.00% 52W High Chg -71.00%
Recommedations 1.70 Quick Ratio 14.85 Shares Outstanding 77.58M 52W Low Chg 5.00%
Insider Own 11.16% ROA -29.25% Shares Float 110.42M Beta 1.07
Inst Own 31.87% ROE -71.72% Shares Shorted/Prior 605.68K/852.32K Price 2.73
Gross Margin 100.00% Profit Margin - Avg. Volume 303,364 Target Price 6.75
Oper. Margin -4,938.20% Earnings Date Aug 28 Volume 484,225 Change -1.44%
About I-MAB

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

I-MAB News
07:00 AM I-Mab to Participate at the Piper Sandler Healthcare Conference
11/17/24 I-Mab Third Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)
11/14/24 I-Mab Reports Third Quarter 2024 Results
11/06/24 I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
10/31/24 I-Mab to Release Q3 2024 Financial Results on November 14, 2024
10/30/24 I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
10/28/24 I-Mab to Participate at the Truist Securities BioPharma Symposium
10/25/24 I-Mab Biopharma’s Strategic US Transition and Pipeline Focus
10/09/24 IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade
09/16/24 I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024
09/10/24 I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
08/30/24 I-Mab First Half 2024 Earnings: US$0.19 loss per share (vs US$1.32 loss in 1H 2023)
08/28/24 I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates
08/26/24 I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
08/14/24 I-Mab to Release 1H 2024 Financial Results on August 28, 2024
08/07/24 I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
07/15/24 I-Mab Announces Leadership Transitions
06/07/24 While private equity firms own 21% of I-Mab (NASDAQ:IMAB), retail investors are its largest shareholders with 59% ownership
06/06/24 I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
06/06/24 I-Mab and BMS assess givastomig for gastric and oesophageal cancer
IMAB Chatroom

User Image JohnTill Posted - 1 day ago

$IMAB Another lesson why you never fall in love with a stock. Story changed dramatically and they raided the assets to benefit the China holders. Thanking my lucky stars for avoiding the disaster. Some powerful players still involved so a run down the road will not surprise but how low do they take it first.

User Image forfun88 Posted - 1 day ago

$IMAB is @JohnTill still in this lol. I remember when he was pumping in the teens. This is still a scam company. Gave away all near term assets to the China entity that is now ran by the original founder of Imab! No earnings calls either. No respect for any of you sheep

User Image ieatbaguette Posted - 1 day ago

$IMAB wow never thought this would hit under a dollar. Kinda scared this may continue falling not sure when to enter so I guess I should start now

User Image Stocksman45 Posted - 2 days ago

@FF355 That’s true and could give $IMAB a much larger cash runway, depending on TJs worth in the market. Current prices are due to RFK spooking the biotech markets. He might actually make FDA approval red tape reduced, which would be good for biotechs not bad.

User Image Stocksman45 Posted - 2 days ago

$IMAB Most biotechs down. RFK. Overblown reaction. If anything he could speed up FDA approval and make it more efficient. “Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.'s potential impact on the FDA.”

User Image iui33 Posted - 2 days ago

$IMAB even tho it looks good on paper, stock price is telling another story. neutral here

User Image serfi Posted - 2 days ago

$IMAB what a beautiful short

User Image iui33 Posted - 3 days ago

$IMAB kept the rights to its entire portfolio outside of China, including eftansomatropin alfa, a long-acting recombinant human growth hormone that scored a phase 3 win last year in children with growth hormone deficiency.

User Image iui33 Posted - 6 days ago

$IMAB 7x from here

User Image FF355 Posted - 6 days ago

$IMAB TJ bio ‘s pipeline . This company alone could be worth couple billions which I-mab owns 15%

User Image FF355 Posted - 1 week ago

$IMAB I-mab ownership in TJ bio is 15%. This alone is larger than the market cap of the company

User Image Wannanchagri Posted - 1 week ago

$IMAB $MNOV 🚨💥🚀🔥 PR is incoming. $BOLT.CN $.31 (+19.23%) average volume increased ~100%. I'm going to add on Monday if it's still this low. Latest News 🚀🤑 Market cap at $5.7M; Whiting’s influence may drive upward movement if new partnerships or exploration progress 1️⃣ Bolt Metals ($BOLT.CN) advances with two key updates: Ben Whiting joins as Technical Advisor, and a C$544,500 private placement closed 💸. 2️⃣ Funding: The placement includes shares and warrants, exercisable at C$0.75 for two years, with proceeds for exploration, working capital, and copper project growth ⚒️

User Image iui33 Posted - 1 week ago

$IMAB just told us it got 15% from a 237m deal. thats half of their current valuation

User Image Stocksman45 Posted - 1 week ago

$IMAB This statement in the earnings reports indicates IMAB now owns 15% (up from 9%) of TJ Bio, the remaining Chinese entity. “I-Mab's ownership in TJ Bio post-settlement of the repurchase obligations is approximately 15%”

User Image Stocksman45 Posted - 1 week ago

$IMAB From company website: https://ir.i-mabbiopharma.com/news-releases/news-release-details/i-mab-reports-third-quarter-2024-results

User Image DonCorleone77 Posted - 1 week ago

$IMAB I-Mab reports Q3 EPS (25c) vs. (39c) last year Reports no revenue in Q3 vs. $315K last year. The company expects its existing cash and cash related balances to be sufficient to fund its current operating plan into 2027. "I-Mab is making excellent progress in advancing the development of our pipeline projects, supported by our strong cash balance, streamlined operating model, and a focused in-licensing strategy," said Sean Fu, CEO. "In addition, Phase 1 data presented this year for uliledlimab, givastomig, and ragistomig at four international medical conferences highlight the strength of our early data sets for each program. These results have provided us with a strong foundation for advancing each molecule into expanded clinical trials, including Phase 2 studies, in the next year."

User Image iui33 Posted - 1 week ago

$IMAB Hangzhou’s TJ Biopharma sold the China rights for its CD73-targeted antibody to Sanofi in a deal worth up to $237 million. 9% belongs ti IMAB also IMAB keeps the rights for the rest of the world. This drug alone worths 500m. Mcap at the moment 80m + 200m at hand. Its a def buy here.

User Image iui33 Posted - 1 week ago

$IMAB givastomig optimum dosage of 8-12 mg/kg. High tumor targeting also. Long story short medium dosage high results. Feature looks bright. Fingers crossed

User Image larsson13 Posted - 2 weeks ago

$IMAB 46k premarket trades so far, weird.

User Image iui33 Posted - 2 weeks ago

$IMAB https://ascopost.com/issues/november-10-2024/fda-approves-novel-combination-regimen-for-gi-cancers/ Soon givastomig

User Image iui33 Posted - 2 weeks ago

$IMAB the low is in

User Image iui33 Posted - 10/30/24

$IMAB for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18.2 (CLDN18.2) and 4-1BB bispecific antibody, at SITC 2024. They are in a harry!!!

User Image iui33 Posted - 10/29/24

$IMAB https://www.benzinga.com/pressreleases/24/09/n40789214/i-mab-presents-positive-uliledlimab-pharmacokinetics-data-at-2024-world-conference-on-lung-cancer These data, plus a previously presented favorable safety profile and clinical efficacy, fortify our view that uliledlimab has the potential to meaningfully improve the care of patients with mNSCLC

User Image iui33 Posted - 10/29/24

$IMAB while they have 207M$ at hand. So you get 2.1 dollars for 1 dollar...

User Image Vsrtrade Posted - 10/25/24

$IMAB the price action is different, long term hold. I just keep adding more

User Image FF355 Posted - 1 month ago

$IMAB the run up starts here. Mark my word

User Image RollingDollars Posted - 1 month ago

$IMAB

User Image Tika1 Posted - 1 month ago

$IMAB After dealing with its Chinese counterpart, is it possible that $SNY is looking to buy or do a deal with $IMAB? Has something been leaked?

User Image SecondChances Posted - 1 month ago

$IMAB news 2 weeks back put a valuation of $12. Long way to go.

User Image larsson13 Posted - 1 month ago

$IMAB where does the vol come from with no news, think this happened 2 weeks ago as well?

Analyst Ratings
HC Wainwright & Co. Buy Sep 17, 24
HC Wainwright & Co. Buy Aug 29, 24
Needham Buy Apr 12, 24
Piper Sandler Overweight Mar 18, 24
HC Wainwright & Co. Buy Mar 18, 24
Needham Buy Mar 15, 24
Needham Buy Feb 8, 24
Needham Buy Sep 25, 23
Cantor Fitzgerald Overweight Sep 5, 23